Primary Hyperoxaluria Type 1 (PH1)
American Society of Nephrology (ASN) 2024
Congress Details
October 24-27, 2024
San Diego, CA, USA
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Congress Materials
Presentation Type
Location
Presenter
Related Materials
Primary Hyperoxaluria Type 1 (PH1)
National Kidney Foundation (NKF) 2025
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial
American Journal of Kidney Diseases
Primary Hyperoxaluria Type 1 (PH1)
International Pediatric Nephrology Association (IPNA) 2025
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial
Frontiers in Pediatrics
Primary Hyperoxaluria Type 1 (PH1)
Reducing diagnostic delays in acute hepatic porphyria using health records data and machine learning
Journal of the American Medical Informatics Association
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial
Kidney International Reports
